Neurology · Philadelphia area, PA
Neurology studies in Philadelphia area, PA
72 recruiting studies have a site in the Philadelphia area. This page includes nearby cities such as Upland, Bryn Mawr, Wynnewood, Abington.
72 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Philadelphia, PA + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Prilenia
- Location
- Philadelphia, PA + 17 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Philadelphia, PA + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Celgene
- Location
- Philadelphia, PA + 13 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Supernus Pharmaceuticals, Inc.
- Location
- Philadelphia, PA + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Philadelphia, PA + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB Biopharma SRL
- Location
- Philadelphia, PA + 41 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 1
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Pfizer
- Location
- Philadelphia, PA + 10 other US sites
- Eligibility basics
- Ages 6–11
- Recruiting
MMA Embolization for Refractory Chronic Migraine
Cerenovus, Part of DePuy Synthes Products, Inc.
- Location
- Philadelphia, PA + 7 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Philadelphia, PA + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 1
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Insmed Gene Therapy LLC
- Location
- Philadelphia, PA + 6 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Philadelphia, PA + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Willow Grove, PA + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Epygenix
- Location
- Philadelphia, PA + 16 other US sites
- Eligibility basics
- Ages 2+
- RecruitingPhase 2/Phase 3
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
DiaMedica Therapeutics Inc
- Location
- Philadelphia, PA + 35 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Philadelphia, PA + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompé Farmaceutici S.p.A
- Location
- Philadelphia, PA + 13 other US sites
- Eligibility basics
- Ages 50–80
- RecruitingPhase 1/Phase 2
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
UniQure Biopharma B.V.
- Location
- Philadelphia, PA + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Octapharma
- Location
- Philadelphia, PA + 5 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Philadelphia, PA + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
Praxis Precision Medicines
- Location
- Philadelphia, PA + 5 other US sites
- Eligibility basics
- Ages 0 mo–18
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Pfizer
- Location
- Philadelphia, PA + 30 other US sites
- Eligibility basics
- Ages 18–45 · Women only
- RecruitingPhase 3
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Neurona Therapeutics
- Location
- Philadelphia, PA + 34 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 4
Two Dose Levels of Privigen in Pediatric CIDP
CSL Behring
- Location
- Philadelphia, PA + 2 other US sites
- Eligibility basics
- Ages 2–17
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.